APA-Zitierstil (7. Ausg.)

Dreger, P. (2018). High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: Integrating molecular and cellular therapies. Blood, 132(9), . https://doi.org/10.1182/blood-2018-01-826008

Chicago-Zitierstil (17. Ausg.)

Dreger, Peter. "High-risk Chronic Lymphocytic Leukemia in the Era of Pathway Inhibitors: Integrating Molecular and Cellular Therapies." Blood 132, no. 9 (2018). https://doi.org/10.1182/blood-2018-01-826008.

MLA-Zitierstil (9. Ausg.)

Dreger, Peter. "High-risk Chronic Lymphocytic Leukemia in the Era of Pathway Inhibitors: Integrating Molecular and Cellular Therapies." Blood, vol. 132, no. 9, 2018, https://doi.org/10.1182/blood-2018-01-826008.